EMA advises on how to prevent medication errors with new forms and indications
This article was originally published in SRA
Executive Summary
In yet another move prompted by the new EU pharmacovigilance legislation, companies proposing to market products similar to ones already on the market are being asked to take extra steps to prevent potential medication errors, particularly involving substances that have a narrow therapeutic index1.